Sequana Medical 2021 BioCapital Europe Presentation

Sequana Medical presented its innovative treatment solutions for diuretic-resistant fluid overload across liver disease, malignant ascites, and heart failure applications. The presentation highlighted the alfapump® system, which was under clinical investigation in the POSEIDON Study, and DSR® therapy in development. The company outlined its clinical pipeline and market opportunity for addressing refractory ascites and fluid overload conditions.